<iframe width="560" height="315" src="https://www.youtube.com/embed/fEBxz7ZVgLU" http://violetmorganonline.accessnetwork.us/2016/07/30/being-a-confident-and-competent-communicator-strengthens-your-credibility-in-the-eyes-of-the-individual-or-group-you-are-trying-to-influence frameborder=”0″ allowfullscreen>
Portola is currently evaluating AndexXa in this global, Phase 3b/4 single-arm, open-label confirmatory study in patients receiving apixaban, rivaroxaban, edoxaban or enoxaparin who present with an acute major bleed. The FDA granted AndexXa Orphan Drug designation, for which Portola would expect to receive seven years of marketing exclusivity if the drug is approved. This designation applies to drugs and biologics intended for the treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the United States. Read More About Portola Pharmaceuticals, Inc. Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola’s partnered program is focused on interview skills harvard developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma. Forward-looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/portola-pharmaceuticals-receives-complete-response-025707586.html
The agency advised those who have traveled to this area since July 14 to be aware that active transmission of the virus is occurring. Pregnant women should talk to their health care providers about testing, and anyone with a partner who is pregnant should follow recommendations to prevent sexual transmission of the virus. Florida Gov. Rick Scott announced Friday that five locally transmitted http://www.malleyandco.com/medicalinterviewpreparation/2016/07/25/indian-colleges-with-a-debating-circuit-boast-of-senior-journalists-ias-officers-politicians-and-more/ cases of the Zika virus have been confirmed in an area of Miami Beach. Three of those individuals were visitors to the area when they contracted the virus. The visitors have returned to their homes in Texas, New York and Taiwan. None of the five people has been identified, although Scott said three are men and two are women. Friday’s developments bring the total number of locally transmitted cases in Florida to 36. The area in Miami Beach is limited to 1 square miles, Scott said, running from the beach to the Intracoastal Waterway and from Eighth Street to 28th Street.
For the original version including any supplementary images or video, visit http://www.wcvb.com/health/local-zika-transmission-confirmed-in-miami-beach/41280454